DHPO

DHPO, or **2-(3,4-dihydro-2H-pyrrolium-1-yl)-3oxoindan-1-olate**, is a novel synthetic small molecule that has shown efficacy in preclinical studies for alleviating impaired glucose tolerance and correcting lipid abnormalities associated with type 2 diabetes. In animal models (genetic and dietary-induced diabetes in mice), DHPO reduced fasting blood glucose, improved glucose disposal, and corrected dyslipidemia. Mechanistically, DHPO increases glucose uptake in skeletal muscle via activation of the AMPK (adenosine monophosphate-activated protein kinase) signaling pathway, as it induces phosphorylation of AMPK and its downstream effector acetyl-CoA carboxylase. These effects were not seen in kinase-dead AMPK-α2 transgenic mice, confirming AMPK dependence. DHPO's action appears to be distinct from classic insulin signaling, as it does not alter phosphorylation of the insulin receptor or Akt[3].